Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's

What It Covers

Gene Mack, president and CEO of Gain Therapeutics, explains how GT02287 targets the GBA1-encoded enzyme glucocerebrosidase to potentially modify Parkinson's disease progression rather than manage symptoms. Phase 1b data from 21 patients in Australia shows biomarker reductions in toxic lipid substrates and early functional improvements.

Key Questions Answered

• •Disease-modifying mechanism: GT02287 acts as a molecular chaperone, binding to and stabilizing the glucocerebrosidase (GCase) enzyme even when misformed by GBA1 genetic mutation, then escorting it through the cell's traffic pathway. This approach targets disease biology directly rather than compensating with dopamine, which loses efficacy as neurons progressively die off.
• •Phase 1b biomarker signal: In a 90-day trial with 21 Parkinson's patients, GT02287 reduced toxic lipid substrate glucosylsphingosine levels in cerebrospinal fluid. Patients entering the study with elevated glucosylsphingosine showed greater clinical improvement than those with lower baseline levels, suggesting a stratification marker for identifying which patients respond most strongly.
• •Patient retention as proxy signal: 16 of 19 patients who completed the initial 90-day phase 1b study voluntarily enrolled in a 12-month open-label extension. The drug is administered as an oral powder suspension mixed with water. Sustained voluntary compliance in a non-blinded setting provides an informal signal that participants perceive functional benefit worth continuing.
• •AI platform ceiling in drug development: Gain's Magellan platform uses physics-based binding kinetics calculations to identify novel druggable allosteric pockets on proteins previously considered undruggable, accelerating bench-to-clinic timelines. However, AI cannot yet compress clinical trial timelines, meaning compound discovery outpaces regulatory validation capacity and creates a structural bottleneck regardless of discovery speed.
• •Phase 2 trial structure: Gain expects FDA IND clearance in Q2 2025, with a phase 2 study launching in Q3 2025 across Australia, Europe, and the US. The trial incorporates secondary endpoints using digital health technologies to capture functional changes not reliably detected by the standard MDS-UPDRS clinical scale, which Mack argues is becoming an insufficient approval benchmark.